Latest news with #FluMist
Medscape
27-06-2025
- Health
- Medscape
New ACIP Supports Previous Universal Flu Vaccination
The CDC's newly appointed Advisory Committee on Immunization Practices (ACIP) voted to recommend annual influenza vaccination for all persons aged 6 months or older with no contraindications. Of the seven members who participated in the vote, the vote was yes to recommend vaccination from six members, with one abstention. The 2024-2025 flu season was classified as high severity across all age groups, said Vivien Dugan, MD, of the CDC's Influenza Division. In children younger than 18 years, a total of 246 influenza-associated deaths from the 2024-2025 season have been reported as of June 7, 2025, she said. Dugan also presented estimates of the disease burden of influenza and the alleviation of this burden via vaccines. Data from multiple surveillance networks showed an overall vaccine coverage rate ranging from 38% to 56% for outpatient visits and 35% to 71% for inpatient visits, with variation by age group and flu type, she said. 'Estimated influenza disease burden was the highest the US has seen in the last decade,' she noted in her presentation. However, vaccination likely prevented approximately 240,000 influenza-related hospitalizations, mainly in adults aged 65 years or older, she said. Flu Vaccination Options Increase Options for influenza vaccination for the upcoming season include not only an injectable vaccine but also the needle-free FluMist nasal spray (live attenuated influenza vaccine, trivalent). A recombinant flu vaccine (Flublok) contains no eggs and was recently approved for use in individuals aged 9 years or older by the FDA after an extensive review of safety and efficacy data. Some of these data were shared at the ACIP meeting. Pedro Folegatti, MD, an employee of Flublok manufacturer Sanofi, presented data on the safety and effectiveness of the latest quadrivalent flu vaccine (RIV4) among individuals aged 9-17 years compared with those aged 18-49 years in a phase 3 study. The RIV4 showed similar safety and effectiveness in a younger age group, with noninferiority of hemagglutination inhibition immune response and a similar safety profile. A trivalent Flublok was approved by the FDA in March 2025 for individuals aged 9 years or older, according to an approval letter. Discuss Different Delivery Systems With Patients 'As influenza vaccines are recommended for all individuals over 6 months of age, having multiple products available increases accessibility, particularly in the rare event that a child has a contraindication to other currently available flu vaccines,' said Lori Handy, MD, MSCE, associate director of the Vaccine Education Center at the Children's Hospital of Philadelphia and assistant professor of clinical pediatrics at the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, in an interview. Having a supply of influenza vaccine that does not rely on eggs puts the US in a better position in the event of influenza pandemics or egg shortages, she noted. Although it is hard to predict whether parents have preferences for different manufacturing processes, the expanded Flublok indication may improve vaccination rates, Handy said. Vaccine Components Similar to Last Year Dugan also presented the influenza vaccine composition for the 2025-2026 season, which includes: ● A/Victoria/4897/2022 (H1N1) pdm09-like virus for egg-based vaccines or an A/Wisconsin/67/2022 (H1N1) pdm09-like virus for cell and recombinant vaccines ● A/Croatia/Y10136RV/2023 (H3N2)-like virus for egg-based vaccines or an A/District of Columbia/27/2023 (H3N2)-like virus for cell and recombinant vaccines ● B/Austria/1359417/2021 (B/Victoria lineage)-like virus The next ACIP meeting is tentatively scheduled for the third quarter of 2025. The study on Flublok was sponsored by manufacturer Sanofi, and Folegatti is employed by Sanofi.
Japan Today
26-06-2025
- Health
- Japan Today
Kennedy's advisers endorse flu vaccines — except for a few targeted by antivaccine activists
Lyn Redwood, a nurse practitioner who once ran the anti-vaccine group that Robert F. Kennedy Jr. founded, attends a meeting of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention in Atlanta on Thursday, June 26, 2025. (AP Photo/Shelby Lum) By MIKE STOBBE and LAURAN NEERGAARD The Trump administration's new vaccine advisers on Thursday endorsed this fall's flu vaccinations for just about every American but threw in a twist: Only use certain shots free of an ingredient antivaccine groups have falsely tied to autism. What is normally a routine step in preparing for the upcoming flu season drew intense scrutiny after U.S. Health Secretary Robert F. Kennedy Jr. abruptly fired the influential 17-member Advisory Committee on Immunization Practices and handpicked replacements that include several vaccine skeptics. That seven-member panel bucked another norm Thursday: It deliberated the safety of a preservative used in less than 5% of U.S. flu vaccinations based on a presentation from an antivaccine group's former leader — without allowing the usual public airing of scientific data from the Centers for Disease Control and Prevention. The preservative, thimerosal, has long been used in certain vaccines that come in multi-dose vials, to prevent contamination as each dose is withdrawn. But it has been controversial because it contains a small amount of a particular form of mercury. Study after study has found no evidence that it causes autism or other harm. Yet since 2001, all vaccines routinely used for U.S. children age 6 years or younger have come in thimerosal-free formulas — including single-dose flu shots that account for the vast majority of influenza vaccinations. The advisory panel first voted, with one abstention, to back the usual U.S. recommendation that nearly everyone age 6 months and older get an annual flu vaccination. Then the advisers decided people should only be given thimerosal-free single-dose formulations, voting 5-1 with one abstention. That would include single-dose shots that already are the most common type of flu vaccination as well as the nasal spray FluMist. It would rule out the subset of flu vaccine that is dispensed in multi-dose vials. 'There is still no demonstrable evidence of harm,' one panelist, Dr. Joseph Hibbeln, a psychiatrist formerly with the National Institutes of Health, said in acknowledging the committee wasn't following its usual practice of acting on evidence. But he added that 'whether the actual molecule is a risk or not, we have to respect the fear of mercury' that might dissuade some people from getting vaccinated. Normally the CDC's director would decide whether to accept ACIP's recommendation, but the Senate has not yet confirmed nominee Susan Monarez. Administration officials said Kennedy would make that decision. While Thursday's debate involved only a small fraction of flu vaccines, some public health experts contend the discussion unnecessarily raised doubt about vaccine safety. Already, fewer than half of Americans get their yearly flu vaccinations, and mistrust in vaccines overall is growing. 'What should have been a rigorous, evidence-based discussion on the national vaccine schedule instead appeared to be a predetermined exercise orchestrated to undermine the well-established safety and efficacy of vaccines and fundamental basics of science,' said Dr. Jason Goldman of the American College of Physicians. Public health experts decried the panel's lack of transparency in blocking the presentation of CDC's analysis of thimerosal that concluded there was no link between the preservative and neurodevelopmental disorders, including autism. The data had been posted on the ACIP's website Tuesday, but was later removed — because, according to ACIP member Dr. Robert Malone, the report hadn't been authorized by Kennedy's office. Committee members said they had read it. The ACIP, created more than 60 years ago, helps the CDC determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available. Kennedy has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Thimerosal was placed on the meeting agenda shortly after Kennedy's new vaccine advisers were named last week. © Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Yahoo
02-04-2025
- Business
- Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million for the year ended December 31, 2023. Warning! GuruFocus has detected 6 Warning Signs with AIM. Release Date: April 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AIM ImmunoTech Inc (AIM) announced a new clinical study evaluating Ampligen in combination with AstraZeneca's FluMist as a potential intranasal vaccine for influenza, including avian flu. The company strengthened its leadership team by adding two experienced Board members, Ted Kellner and David Chemerow, to guide strategic execution. The Erasmus Medical Center Safety Committee approved the continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial, marking progress in their clinical programs. AIM ImmunoTech Inc (AIM) reported final clinical results from the AMP-518 study, reinforcing Ampligen's potential in treating post-COVID conditions. The company expanded its intellectual property estate with new patents in the US and Netherlands, enhancing protection for Ampligen's applications. AIM ImmunoTech Inc (AIM) reported a decrease in cash, cash equivalents, and marketable securities to approximately $4 million as of December 31, 2024. Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating potential budget constraints. General and administrative expenses also decreased from $21.1 million in 2023 to $13.7 million in 2024, which may reflect cost-cutting measures. The company is facing challenges in maintaining its listing on the New York Stock Exchange American and is considering a reverse stock split to avoid delisting. Future clinical trials will require additional manufacturing of Ampligen, which necessitates capital investment and could pose a financial challenge. Q: Do you have adequate supply of Ampligen for all your clinical trials this year, and how easy would it be to get new supply? A: Thomas Equels, President, CEO, and Executive Vice Chairman, responded that they have a budget for Ampligen tied to ongoing clinical activities, ensuring sufficient supply for current trials. For future trials, manufacturing more Ampligen will require capital, but they are actively working with polymer manufacturers and other vendors to ensure a steady supply. They do not anticipate any supply issues unless unforeseen circumstances arise. Q: What are the financial highlights for AIM ImmunoTech for the year ended December 31, 2024? A: Thomas Equels noted that AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Research and development expenses were $6.2 million, down from $10.9 million in 2023. General and administrative expenses were $13.7 million, compared to $21.1 million in 2023. Q: What steps are being taken to maintain AIM ImmunoTech's listing on the New York Stock Exchange American? A: Thomas Equels emphasized that maintaining the listing is a major priority. They are evaluating all available options to maintain compliance, including a potential reverse stock split. A special meeting of stockholders will be held to authorize the Board to effect the reverse stock split to avoid delisting. Q: Can you provide an update on the DURIPANC pancreatic cancer trial? A: Thomas Equels stated that the Erasmus Medical Center Safety Committee has approved the continuation into the Phase 2 portion of the DURIPANC trial, which evaluates Ampligen in combination with AstraZeneca's Imfinzi. Dosing for Phase 2 has commenced, and they anticipate enrolling the final patient by the second or third quarter of 2026. Q: What are the upcoming milestones for AIM ImmunoTech's clinical programs? A: Thomas Equels highlighted several milestones, including the completion of a Phase 2 study in advanced ovarian cancer in the first half of 2025, the dosing of the first patient in a refractory melanoma study in the first half of 2025, and the completion of enrollment for a Stage 4 triple negative breast cancer trial by the second quarter of 2026. They are also planning a follow-up study for long COVID and a new clinical study evaluating Ampligen with FluMist for influenza. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
28-02-2025
- Health
- Associated Press
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM' or the 'Company') today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham ('UAB'), has agreed to act as the Principal Investigator for the company's planned clinical study in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. Ampligen would serve as a vaccine adjuvant. This will be a follow-up study to a previous clinical trial at UAB, which indicated that intranasal delivery of Ampligen after the intranasal delivery of the FluMist seasonal influenza vaccine not only increased the immune response to seasonal variants in the vaccine by greater than four-fold, but most importantly induced cross-reactive secretory Immunoglobulin A against highly pathogenic avian influenza virus strains H5N1, H7N9 and H7N3. Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: 'I'm excited for the opportunity to follow-up on my previous work regarding the combination of Ampligen and FluMist, especially with the rising threat of avian influenza.' AIM has engaged Amarex Clinical Research, its Clinical Research Organization, with the preparation of an Investigational New Drug application and the eventual management of the planned clinical study. A key next step will be to identify study funding through industry or governmental grants. AIM CEO Thomas K. Equels states: 'Our strong belief in the potential of a second Ampligen and FluMist study in humans stems directly from the pre-clinical and clinical work performed with Ampligen and multiple influenza variants, including in the original UAB study. We believe that the U.S. government — which has made the growing threat of avian influenza a top priority — should take a long and close look at this data when deciding how best to prepare for a potential epidemic. Rather than spend perhaps billions of dollars on the lengthy development of a new mRNA vaccine, the government should instead consider the combination of Ampligen and FluMist, which would be no more than $10 million in development costs and far quicker to develop, since it already has strong human and non-human primate data suggesting its potential preventive efficacy against avian influenza. AIM believes that the potential for a rapidly deployable vaccine that includes Ampligen is clear.' Read more about the Ampligen-involved avian influenza pre-clinical and clinical work here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc., an Ocala, Florida-based company, is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy or vaccine adjuvant for any variant of influenza. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Yahoo
20-02-2025
- Health
- Yahoo
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032
The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination. The market growth is largely fueled by the increasing uptake of the influenza vaccine and government efforts to raise awareness and encourage vaccination. LAS VEGAS, Feb. 20, 2025 /PRNewswire/ -- DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading influenza vaccine companies' market shares, challenges, influenza vaccine market drivers, barriers, trends, and key market influenza vaccine companies in the market. Key Takeaways from the Influenza Vaccine Market Report As per DelveInsight estimates, North America is anticipated to dominate the global influenza vaccine market during the forecast period. In the type segment of the influenza vaccine market, the inactivated influenza vaccine category generated a significant revenue share in the influenza vaccine market in 2024. Notable influenza vaccine companies such as GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, and several others, are currently operating in the influenza vaccine market. In December 2024, Sanofi revealed that its two combination vaccine candidates, aimed at preventing both influenza and COVID-19 in individuals aged 50 and older, have been granted fast-track designation by the FDA. In September 2024, FluMist was approved in the US as the only self-administered influenza vaccine. This needle-free nasal spray can be used by adults up to 49 years old or administered by a parent or caregiver to children aged 2-17. In April 2024, CureVac SE announced the commencement of Phase 1 for a collaborative venture with GSK marking the initiation of a combined Phase 1/2 investigation into an experimental pre-pandemic vaccine targeting influenza A (H5N1). This is a monovalent vaccine candidate based on mRNA technology and encodes an influenza A H5-antigen. In October 2023, Moderna, Inc. announced the interim findings from the Phase 1/2 trial of mRNA-1083, a potential combination vaccine addressing both influenza and COVID-19, have been reported as favorable. mRNA-1083 showed a strong immunogenicity and safety profile against influenza. To read more about the latest highlights related to the influenza vaccine market, get a snapshot of the key highlights entailed in the Global Influenza Vaccine Market Report Influenza Vaccine Overview The influenza vaccine is a crucial preventive measure against the seasonal flu, which is caused by influenza viruses that mutate frequently. The vaccine is updated annually to protect against the most prevalent strains, typically including both influenza A and B viruses. It works by stimulating the immune system to produce antibodies that recognize and combat the virus, reducing the severity of illness and preventing complications such as pneumonia, hospitalization, and death. Influenza vaccines are available in different formulations, including inactivated (flu shots) and live attenuated (nasal spray) versions, catering to different age groups and medical conditions. Widespread vaccination is essential for public health, especially for high-risk groups such as young children, elderly individuals, pregnant women, and those with chronic conditions like asthma or heart disease. The flu vaccine also helps reduce the burden on healthcare systems by lowering the number of flu-related hospitalizations and medical visits. While the vaccine's effectiveness varies from year to year, studies consistently show that it significantly reduces the risk of severe illness. Public health organizations, such as the WHO and CDC, recommend annual flu vaccination as the best strategy for preventing influenza outbreaks and maintaining community immunity. Influenza Vaccine Market Insights North America held the largest share of the influenza vaccine market in 2024, driven by an increase in influenza cases across the region. In the assessment done by DelveInsight, the estimated total number of medical visits related to seasonal influenza in the US were 16 million in 2023. Type-specific cases of seasonal influenza were categorized into two types, Type A and Type B. The United States showed the highest cases of Type A compared to other 7MM countries. In 2023, the US, alone accounted for approximately 55% of total cases of Type A influenza. In 2023, the total vaccinated population was estimated to be 383 million in the 7MM. The highest vaccinated population was seen in the US. Furthermore, regional government efforts to prevent and treat the flu are playing a key role. For instance, in July 2022, GSK plc entered into a partnership with the Government of Canada to provide both pandemic and seasonal influenza vaccines for the protection of Canadian adults and children. As part of this agreement, GSK committed to supplying up to 80 million doses of pandemic influenza vaccine in the event of a pandemic, along with 16 million doses of seasonal influenza vaccine throughout the contract period. These are some of the factors contributing to the growth of the influenza vaccine market in the region. To know more about why North America is leading the market growth in the influenza vaccine market, get a snapshot of the Influenza Vaccine Market Outlook Influenza Vaccine Market Dynamics The influenza vaccine market is influenced by several dynamics, primarily driven by public health needs, vaccine efficacy, and technological advancements in vaccine development. Annual flu seasons create a constant demand for vaccines, as different strains of the virus circulate each year. This necessitates the formulation of updated vaccines, which boosts the demand for production. Leading vaccine manufacturers, such as Sanofi, GlaxoSmithKline, and Seqirus, dominate the market, but competition is emerging from smaller biotech firms focusing on novel vaccine platforms, such as mRNA technology. The market is also impacted by government procurement programs, especially during pandemic outbreaks or seasonal flu spikes. Countries around the world, particularly in regions with a higher prevalence of flu-related hospitalizations and deaths, invest heavily in vaccination programs. The rise in vaccination awareness, bolstered by media campaigns and educational efforts, has further stimulated vaccine uptake. Additionally, global initiatives, such as GAVI and the World Health Organization's support for immunization in low-income countries, are increasing access to vaccines and expanding market reach. Vaccine technology plays a critical role in market dynamics. Traditional egg-based vaccine production is being replaced by cell-based and recombinant DNA technologies, which are faster and more scalable. The emergence of mRNA vaccines, as seen in the COVID-19 pandemic, has introduced a new era of possibilities for influenza vaccines, promising better efficacy and faster production timelines. However, challenges remain, including the high cost of development and production, especially for mRNA vaccines, which may limit their accessibility in certain markets. Finally, consumer behavior and demographic trends are shaping the market. In developed countries, the elderly and those with chronic conditions are the primary recipients of the flu vaccine, driving demand. Meanwhile, the increasing acceptance of flu vaccinations among healthy adults and children is expanding the market base. At the same time, factors like vaccine hesitancy, misinformation, and accessibility issues in rural or underdeveloped regions present ongoing challenges. Nevertheless, continued advancements in vaccine research and public health policy are expected to drive growth in the global influenza vaccine market. Get a sneak peek at the influenza vaccine market dynamics @ Influenza Vaccine Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 Influenza Vaccine Market CAGR ~7% Influenza Vaccine Market Size by 2032 USD 14 Billion Key Influenza Vaccine Companies GSK plc, Pfizer Inc., BioNTech, SINOVAC, Moderna, Inc., Merck & Co., Inc., Sanofi, AstraZeneca, CSL, Abbott, Novavax, Gilead Sciences, Inc., Serum Institute Of India Pvt. Ltd., DAIICHI SANKYO COMPANY, LIMITED, Novartis AG, Cadila Pharmaceuticals, Boehringer Ingelheim International GmbH, Zydus Pharmaceuticals, Inc., Panacea Biotec, Bharat Biotech, among others Influenza Vaccine Market Assessment Influenza Vaccine Market Segmentation Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the influenza vaccine market are set to emerge as the trendsetter explore @ Influenza Vaccine Companies Table of Contents 1 Influenza Vaccine Market Report Introduction 2 Influenza Vaccine Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Influenza Vaccine Market Key Factors Analysis 6 Influenza Vaccine Market Porter's Five Forces Analysis 7 Influenza Vaccine Market Layout 8 Influenza Vaccine Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the influenza vaccine market by 2032? Click to get a snapshot of the Influenza Vaccine Market Trends Related Reports Vaccine Adjuvants Market Vaccine Adjuvants Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccine adjuvants companies, including Dynavax Technologies, GSK plc, Croda International plc, SEPPIC, Novavax, SPI Pharma, Agenus Inc., Aurorium, Merck KGaA, Vaxine Pty Ltd., Hawaii Biotech Inc., CSL, OZ Biosciences, InvivoGen, Allergy Therapeutics, EUBIOLOGICS CO., LTD., Pacific GeneTech Limited, Riboxx GmbH, CaPtivate Pharmaceuticals LLC, Mukta Industries, among others. Vaccines Market Vaccines Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccines companies, including GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological, among others. Seasonal Influenza Market Seasonal Influenza Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key seasonal influenza companies, including SAb Biotherapeutics, Inc., Emergo Therapeutics, Inc., AlloVir, Cocrystal Pharma, Poolbeg Pharma, Ridgeback Biotherapeutics, Viriom, Inc., NanoViricides, Evrys Bio, ETHRIS, Kino Pharma, among others. Influenza Pipeline Influenza Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur info@ +14699457679https:// Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
